Medicus Pharma

Medicus Pharma

MDCX

Medicus Pharma Ltd. (TSXV: MDCX) is a Canadian clinical-stage biopharmaceutical company. Its primary business focus is the development of non-invasive therapeutic solutions for skin cancers. The company’s core technology is the SkinJect™ platform, an intralesional delivery system designed to administer treatments directly into skin lesions. The company’s key therapeutic area is dermatological oncology. Its lead product candidate, SKNJCT-001, is a novel formulation being investigated for the treatment of basal cell carcinoma. This program is currently in Phase II clinical trials. The intralesional approach aims to provide a potential alternative to surgical excision for certain skin cancers. As a publicly traded entity, Medicus Pharma is listed on the TSX Venture Exchange under the ticker MDCX. The company’s research and development activities are centered on advancing its clinical pipeline through the regulatory process to address unmet needs in dermatology and skin cancer care.

MDCX · Stock Price

USD 0.49-2.81 (-85.03%)
Market Cap: $12.4M

Historical price data

About

Medicus Pharma Ltd. (TSXV: MDCX) is a Canadian clinical-stage biopharmaceutical company. Its primary business focus is the development of non-invasive therapeutic solutions for skin cancers. The company’s core technology is the SkinJect™ platform, an intralesional delivery system designed to administer treatments directly into skin lesions. The company’s key therapeutic area is dermatological oncology. Its lead product candidate, SKNJCT-001, is a novel formulation being investigated for the treatment of basal cell carcinoma. This program is currently in Phase II clinical trials. The intralesional approach aims to provide a potential alternative to surgical excision for certain skin cancers. As a publicly traded entity, Medicus Pharma is listed on the TSX Venture Exchange under the ticker MDCX. The company’s research and development activities are centered on advancing its clinical pipeline through the regulatory process to address unmet needs in dermatology and skin cancer care.

BiotechDermatology